CDK1 and cancer: Furthermore, Vassilev et al (32) previously identified a selective small-molecule inhibitor of Cdk1 that reversibly arrests human cells at the G2/M phase and induces apoptosis in tumor cells, indicating that selective Cdk1 inhibitors may have potential clinical utility in cancer therapy.